Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 46

1.

Antipsychotic polypharmacy in children and adolescents at discharge from psychiatric hospitalization.

Saldaña SN, Keeshin BR, Wehry AM, Blom TJ, Sorter MT, DelBello MP, Strawn JR.

Pharmacotherapy. 2014 Aug;34(8):836-44. doi: 10.1002/phar.1453. Epub 2014 Jul 3.

PMID:
24990538
2.

Aripiprazole in the treatment of challenging behaviour in adults with autism spectrum disorder.

Jordan I, Robertson D, Catani M, Craig M, Murphy D.

Psychopharmacology (Berl). 2012 Oct;223(3):357-60. doi: 10.1007/s00213-012-2723-z. Epub 2012 Apr 26.

PMID:
22535309
3.

[Proper antibiotic therapy. From penicillin to pharmacogenomic].

Caramia G, Ruffini E.

Minerva Pediatr. 2012 Apr;64(2):225-37. Review. Italian.

PMID:
22495196
4.

Young mania rating scale line item analysis in pediatric subjects with bipolar I disorder treated with aripiprazole in a short-term, double-blind, randomized study.

Mankoski R, Zhao J, Carson WH, Mathew SJ, Forbes RA.

J Child Adolesc Psychopharmacol. 2011 Aug;21(4):359-64. doi: 10.1089/cap.2010.0100. Epub 2011 Aug 8.

PMID:
21823911
5.

Agitation in the inpatient psychiatric setting: a review of clinical presentation, burden, and treatment.

Hankin CS, Bronstone A, Koran LM.

J Psychiatr Pract. 2011 May;17(3):170-85. doi: 10.1097/01.pra.0000398410.21374.7d. Review.

PMID:
21586995
6.

Psychiatric assessment of aggressive patients: a violent attack on a resident.

Antonius D, Fuchs L, Herbert F, Kwon J, Fried JL, Burton PR, Straka T, Levin Z, Caligor E, Malaspina D.

Am J Psychiatry. 2010 Mar;167(3):253-9. doi: 10.1176/appi.ajp.2009.09010063.

PMID:
20194488
7.

A double-blind placebo-controlled discontinuation study of zuclopenthixol for the treatment of aggressive disruptive behaviours in adults with mental retardation - secondary parameter analyses.

Hässler F, Glaser T, Pap AF, Beneke M, Diefenbacher A, Reis O; Zuclopenthixol Disruptive Behavior Study Group.

Pharmacopsychiatry. 2008 Nov;41(6):232-9. doi: 10.1055/s-0028-1082072. Epub 2008 Dec 9.

PMID:
19067260
8.

Behavior management on an acute brain injury unit: evaluating the effectiveness of an interdisciplinary training program.

Beaulieu C, Wertheimer JC, Pickett L, Spierre L, Schnorbus T, Healy W, Palmer C, Jones A.

J Head Trauma Rehabil. 2008 Sep-Oct;23(5):304-11. doi: 10.1097/01.HTR.0000336843.60961.b7.

PMID:
18815507
9.

Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients.

Krakowski MI, Czobor P, Nolan KA.

J Clin Psychopharmacol. 2008 Oct;28(5):485-93. doi: 10.1097/JCP.0b013e3181855cd6.

PMID:
18794642
10.

Antipsychotics for BPSD: an audit of prescribing practice in a specialist psychiatric inpatient unit.

Haw C, Stubbs J, Yorston G.

Int Psychogeriatr. 2008 Aug;20(4):790-9. doi: 10.1017/S1041610208006819. Epub 2008 Feb 29.

PMID:
18307825
11.

Addition of antipsychotics to medication regimens during schizophrenic inpatient care.

Koyama A, Ito H, Nakanishi M, Sawamura K, Higuchi T.

Psychiatry Clin Neurosci. 2008 Feb;62(1):56-64. doi: 10.1111/j.1440-1819.2007.01776.x.

PMID:
18289142
12.
13.

Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility.

Citrome L, Shope CB, Nolan KA, Czobor P, Volavka J.

Int Clin Psychopharmacol. 2007 Nov;22(6):356-62.

PMID:
17917554
14.

Insight into illness and adherence to psychotropic medications are separately associated with violence severity in a forensic sample.

Alia-Klein N, O'Rourke TM, Goldstein RZ, Malaspina D.

Aggress Behav. 2007 Jan-Feb;33(1):86-96.

PMID:
17441009
15.

Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis.

Gobbi G, Gaudreau PO, Leblanc N.

J Clin Psychopharmacol. 2006 Oct;26(5):467-73.

PMID:
16974186
16.

Evaluation of factors influencing medication compliance in inpatient treatment of psychotic disorders.

Janssen B, Gaebel W, Haerter M, Komaharadi F, Lindel B, Weinmann S.

Psychopharmacology (Berl). 2006 Aug;187(2):229-36. Epub 2006 May 19.

PMID:
16710714
17.
18.

Risperidone: an open-label, observational study of the efficacy, tolerability, and prescribing behavior in acutely exacerbated patients with schizophrenia.

Pajonk FG, Schreiner A, Peters S, Rettig K, Degner D, Rüther E.

J Clin Psychopharmacol. 2005 Aug;25(4):293-300. Erratum in: J Clin Psychopharmacol. 2006 Feb;26(1):26.

PMID:
16012270
19.

Intramuscular ziprasidone for acute agitation in adolescents.

Hazaray E, Ehret J, Posey DJ, Petti TA, McDougle CJ.

J Child Adolesc Psychopharmacol. 2004 Fall;14(3):464-70.

PMID:
15650504
20.

Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol.

Volavka J, Czobor P, Nolan K, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Cooper TB, Lieberman JA.

J Clin Psychopharmacol. 2004 Apr;24(2):225-8.

PMID:
15206671
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk